ImmunityBio, Inc. (IBRX) Faces Securities Class Action Lawsuit; Investors with Losses Notified
AI-Summarized Article
ClearWire's AI summarized this story from GlobeNewswire into a neutral, comprehensive article.
Key Points
- The Gross Law Firm has issued a notice regarding a securities class action lawsuit against ImmunityBio, Inc. (IBRX).
- The lawsuit alleges violations of federal securities laws due to false or misleading statements and/or omissions by the company and its executives.
- Shareholders who purchased IBRX shares during the class period and incurred losses are being notified and may seek to lead the class action.
- The legal action aims to recover damages for investors allegedly harmed by the company's conduct.
The Gross Law Firm has issued a notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) regarding a securities class action lawsuit. This notice, released on April 10, 2026, by GlobeNewswire, informs investors who purchased shares of IBRX during a specified period that they may be eligible to lead the class action.
The lawsuit alleges that ImmunityBio, Inc. and certain of its executives violated federal securities laws by making materially false and misleading statements and/or failing to disclose material adverse facts. These alleged misrepresentations and omissions concern the company's business, operations, and prospects, which reportedly led to artificial inflation of the company's stock price during the class period. When the true facts were allegedly revealed, the stock price declined, causing losses to investors.
Shareholders who incurred losses from their investment in ImmunityBio, Inc. are encouraged to contact The Gross Law Firm to discuss their legal options. The firm is actively seeking lead plaintiffs for the class action, with a deadline for filing to be appointed as lead plaintiff. This legal action aims to recover damages for investors who were allegedly harmed by the company's actions.
Found this story useful? Share it:
Sources (1)
GlobeNewswire
"IBRX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ImmunityBio, Inc. Securities Lawsuit — The Gross Law Firm"
April 10, 2026